"Three down, one to go. Gilead Sciences met the main goals of two Phase III studies with its blockbuster hopeful sofosbuvir in patients with hepatitis C virus. The biopharma giant aims to use the results from the late-stage studies as part of a larger data package, which will go to the FDA later this year in the company's bid to advance the first all-oral attack on the liver-damaging disease."

To read more: Gilead passes two Phase III tests with key hep C pill - FierceBiotech http://www.fiercebiotech.com/story/gilead-passes-two-phase-iii-tests-key-hep-c-pill/2013-02-04#ixzz2JxOA6nir